Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
Want to see LEGN full AI Analyst Report?
Earnings Data
Report Date
Aug 18, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.06Last Year’s EPS
-0.34Same Quarter Last Year
Strong Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and operational performance—notably robust CARVYKTI sales growth (52% YoY), improved manufacturing metrics (99% success, 29-day turnaround), deeper earlier-line penetration (41% vs 29% YoY), a solid cash position (~$835M), and a clear path to adjusted profitability in 2026. These positives are tempered by a near-term gross margin hit (41% vs 57% prior quarter) from one-time manufacturing ramp costs, an adjusted net loss still present in Q1, event-driven uncertainty around pivotal readouts (CARTITUDE-5/6), and early-stage clinical risk for the In Vivo programs where safety/efficacy data are not yet disclosed. On balance, the highlights (strong growth, manufacturing execution, expanding pipeline, balance sheet strength, path to profitability) outweigh the lowlights, supporting a constructive view of the company's near- to mid-term outlook.Company Guidance
Strong CARVYKTI Sales Growth
CARVYKTI net trade sales of approximately $597 million in Q1 2026, representing 52% year-over-year growth (36% U.S. YoY; >200% ex-U.S. YoY) and 8% sequential growth vs Q4 2025.
Operational and Manufacturing Excellence
Manufacturing success rate of 99%, median turnaround time of ~29 days, and >95% on-time order releases, demonstrating reliable supply and support for broader adoption.
Earlier-Line Penetration Accelerating
Patients in second and third line represented 41% of CARVYKTI apheresis volume in the U.S. in Q1 2026, up from 29% a year ago, indicating meaningful shift toward earlier use and community adoption.
Global Commercial Footprint Expansion
CARVYKTI available across 18 global markets and >300 global treatment sites; 148 authorized U.S. treatment centers (about one-third community), supporting scale and access.
Improving Profitability Trajectory
Company expects company-wide adjusted profitability in 2026. Q1 adjusted net loss narrowed to $11 million ($0.03 per diluted share) vs adjusted net loss of $27 million ($0.07) in Q1 2025, reflecting substantial improvement.
Healthy Balance Sheet and Cash Position
Ended Q1 with approximately $835 million in cash, cash equivalents and time deposits and no long-term debt, providing flexibility to invest in pipeline and manufacturing.
Pipeline Progress and Near-Term Data
Multiple In Vivo and next-generation programs advancing: BCMA In Vivo (autoimmune) and GPRC5D In Vivo (multiple myeloma) in Phase I; LB2501 (CD19/CD20 In Vivo) in Phase I for NHL with potential first clinical data planned for a major meeting midyear; expectation to file 1–2 U.S. INDs in 2026.
Collaboration Revenue Supporting Scale
Collaboration revenue of approximately $298 million in Q1 (primarily related to CARVYKTI/J&J collaboration), contributing to total revenue of $305 million for the quarter.
LEGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LEGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 10, 2026 | $19.14 | $19.56 | +2.19% |
Nov 12, 2025 | $32.03 | $31.18 | -2.67% |
Aug 11, 2025 | $37.00 | $36.24 | -2.05% |
May 13, 2025 | $32.38 | $31.08 | -4.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Legend Biotech Corporation (LEGN) report earnings?
Legend Biotech Corporation (LEGN) is schdueled to report earning on Aug 18, 2026, After Close (Confirmed).
What is Legend Biotech Corporation (LEGN) earnings time?
Legend Biotech Corporation (LEGN) earnings time is at Aug 18, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LEGN EPS forecast?
LEGN EPS forecast for the fiscal quarter 2026 (Q2) is 0.06.